Review ArticleMitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?Brinkman, Keesa; Kakuda, Thomas N.bAuthor Information aDepartment of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; and bDepartment of Clinical and Experimental Pharmacology, Antiviral Pharmacology Laboratory, University of Minnesota, Minneapolis, USA Correspondence to Kees Brinkman, MD, PhD, Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, PO Box 95500, 1090 HM Amsterdam, the Netherlands e-mail: firstname.lastname@example.org Current Opinion in Infectious Diseases: February 2000 - Volume 13 - Issue 1 - p 5-11 Buy Abstract Nucleoside reverse transcriptase inhibitors suppress HIV replication by blocking reverse transcriptase, an RNA-dependent DNA polymerase. These drugs can also affect cellular and mitochondrial DNA polymerases. Mitochondrial DNA polymerase γ is particularly sensitive to nucleoside reverse transcriptase inhibitors, and the majority of adverse effects caused by nucleoside reverse transcriptase inhibitors are most likely caused by mitochondrial dysfunction. This article reviews the recent clinical implications of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity and discusses options for management. © 2000 Lippincott Williams & Wilkins, Inc.